Bellecapital International Ltd. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Bellecapital International Ltd. cut its Regeneron stake by 16.8% in Q4, selling 4,670 shares and retaining 23,109 shares valued at $17.84 million, which is 3.2% of its holdings and its ninth-largest position.
• Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback, but shares fell as net income declined ~10% YoY and several analysts trimmed models or targets.
• Insiders sold 3,774 shares (~$2.94M) over the quarter (insiders now own 7.02%) while institutions hold 83.31% of the stock; consensus rating is a "Moderate Buy" with a price target near $826.59.

Bellecapital International Ltd. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,109 shares of the biopharmaceutical company's stock after selling 4,670 shares during the period. Regeneron Pharmaceuticals comprises 3.2% of Bellecapital International Ltd.'s holdings, making the stock its 9th biggest holding. Bellecapital International Ltd.'s holdings in Regeneron Pharmaceuticals were worth $17,837,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Dodge & Cox grew its position in Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company's stock valued at $2,558,804,000 after acquiring an additional 724,562 shares during the last quarter. AQR Capital Management LLC grew its position in Regeneron Pharmaceuticals by 528.7% in the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company's stock valued at $405,596,000 after acquiring an additional 606,612 shares during the last quarter. Invesco Ltd. grew its position in Regeneron Pharmaceuticals by 38.0% in the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company's stock valued at $834,675,000 after acquiring an additional 408,649 shares during the last quarter. Caisse de depot et placement du Quebec grew its holdings in shares of Regeneron Pharmaceuticals by 115.4% during the third quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company's stock worth $260,051,000 after purchasing an additional 247,780 shares during the last quarter. Finally, Man Group plc grew its holdings in shares of Regeneron Pharmaceuticals by 257.6% during the third quarter. Man Group plc now owns 271,707 shares of the biopharmaceutical company's stock worth $152,773,000 after purchasing an additional 195,724 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a "sector perform" stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today's weaker price action. Regeneron drops despite Q1 beat

Insider Activity

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the business's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares of the company's stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,774 shares of company stock worth $2,942,738 over the last quarter. 7.02% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on REGN shares. Cantor Fitzgerald restated an "overweight" rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an "equal weight" rating in a report on Friday, April 10th. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a "buy" rating in a report on Friday. Piper Sandler started coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They set an "overweight" rating and a $875.00 price target on the stock. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $826.59.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $701.42 on Monday. The company has a market cap of $74.15 billion, a price-to-earnings ratio of 17.09, a P/E/G ratio of 1.60 and a beta of 0.30. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The business has a 50 day moving average price of $756.81 and a 200-day moving average price of $737.56. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company's quarterly revenue was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $8.22 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.05 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.